March 10, 2026
Sandoz bets on its own new biosimilar unit with a veteran hire
A structural reorganization and a key appointment reveal a company that has moved beyond proving itself and is now building for dominance
Pharmaceuticals, Biotechnology and Life Sciences
A structural reorganization and a key appointment reveal a company that has moved beyond proving itself and is now building for dominance
Samsung Bioepis’ BRENZYS™ (etanercept) becomes available in Brazil through Brazil’s public health system, Sistema Único de Saúde (SUS) Established seven…